Protalix BioTherapeutics Director Schwartz Aharon Buys 129000 Shares at $1.6/Share.

Protalix BioTherapeutics, Inc. (PLX) has announced that Director Schwartz Aharon has made a significant investment in the company, acquiring 129,000 shares at a price of $1.6 per share on June 10, 2025.

Protalix BioTherapeutics, Inc. (PLX) has seen a significant investment from its Director, Schwartz Aharon. On June 10, 2025, Aharon acquired 129,000 shares of the company at a price of $1.6 per share [3]. This transaction was executed in multiple trades, with prices ranging from $1.60 to $1.575 per share, reflecting a weighted average purchase price of $1.596 [3].

Aharon's investment highlights his confidence in Protalix's future prospects, particularly its innovative plant cell-based protein expression system, ProCellEx. This system represents a new method for developing recombinant proteins at an industrial scale, with Protalix being the first company to gain U.S. Food and Drug Administration (FDA) approval for a protein produced through this method [1][2].

Protalix's product pipeline includes several promising candidates, such as PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout, and PRX–119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases. The company has also partnered with Pfizer Inc. for the development and commercialization of taliglucerase alfa, a recombinant therapeutic protein for Gaucher disease, and with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio [1][2].

Aharon's investment comes amidst Protalix's preparations to release its financial results for the second quarter of 2025, scheduled for August 14, 2025. Management will host a conference call and webcast to discuss the financial results and provide an update on recent corporate and regulatory developments [1][2].

References:
[1] https://finance.yahoo.com/news/protalix-biotherapeutics-announce-second-quarter-165300213.html
[2] https://www.morningstar.com/news/pr-newswire/20250807ln46644/protalix-biotherapeutics-to-announce-second-quarter-2025-financial-and-business-results-on-august-14-2025
[3] https://www.stocktitan.net/sec-filings/PLX/form-4-protalix-bio-therapeutics-inc-insider-trading-activity-7604d5fffad5.html